TGF-β / Smad Signaling

The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-   B6096 SIS3Summary: Smad3 inhibitor B6096 SIS3Summary: Smad3 inhibitor
-   A3771 RKI-1447Target: ROCKSummary: Potent ROCK1/ROCK2 inhibitor A3771 RKI-1447Target: ROCKSummary: Potent ROCK1/ROCK2 inhibitor
-   A5602 SB525334Summary: (TGF-beta1) receptor inhibitor A5602 SB525334Summary: (TGF-beta1) receptor inhibitor
-   B2288 PirfenidoneSummary: TGF-β production inhibitor B2288 PirfenidoneSummary: TGF-β production inhibitor
-   A8192 Staurosporine6 CitationSummary: serine/threonine protein kinases inhibitor A8192 Staurosporine6 CitationSummary: serine/threonine protein kinases inhibitor
-   A3642 NarciclasineSummary: Modulates the Rho/ROCK/LIM kinase/cofilin pathway A3642 NarciclasineSummary: Modulates the Rho/ROCK/LIM kinase/cofilin pathway
-   A3660 Nilotinib monohydrochloride monohydrateSummary: Bcr-Abl inhibitor A3660 Nilotinib monohydrochloride monohydrateSummary: Bcr-Abl inhibitor
-   B2287 LY3649471 CitationSummary: inhibitor of TGF-β type I receptor kinase domain B2287 LY3649471 CitationSummary: inhibitor of TGF-β type I receptor kinase domain
-   A3017 Dasatinib (BMS-354825)14 CitationSummary: Src and Bcr-Abl inhibitor A3017 Dasatinib (BMS-354825)14 CitationSummary: Src and Bcr-Abl inhibitor
-   A3306 Chelerythrine ChlorideTarget: PKCSummary: PKC antagonist A3306 Chelerythrine ChlorideTarget: PKCSummary: PKC antagonist
